menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Announces Upcoming Investor Event to Present Interim Clinical Data from Ongoing First-in-Human Studies of NTLA-2002 and NTLA-2001 on September 16, 2022

Review of first clinical data from ongoing Phase 1/2 Study of NTLA-2002 for the treatment of hereditary angioedema (HAE) presented at the 2022 Bradykinin Symposium Event to include interim safety and serum TTR reduction data from the cardiomyopathy arm of the Phase 1 study of NTLA-2001 for the
Read More

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

NTLA-2002, an in vivo genome editing candidate designed to prevent angioedema attacks in patients with hereditary angioedema (HAE) after a single dose, is currently being evaluated in a Phase 1/2 study CAMBRIDGE, Mass. , Sept. 01, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Read More

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin Symposium

First clinical data on safety and activity of NTLA-2002, Intellia’s second systemically administered in vivo CRISPR candidate CAMBRIDGE, Mass. , Aug. 23, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing
Read More

Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress

Completed dose-escalation portion of the ongoing Phase 1 study of NTLA-2001 in patients with transthyretin (ATTR) amyloidosis with cardiomyopathy; expects to present interim safety and serum TTR reduction data in 2H 2022 Presented updated interim data from the dose-escalation portion of the
Read More

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates

CAMBRIDGE, Mass. , July 27, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its second quarter 2022 financial results and
Read More

Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose

Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohorts Pharmacokinetic modeling and simulation indicated that an 80 mg fixed dose provides similar exposure to the 1.0 mg/kg dose, where
Read More

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

Oral presentation to include additional durability data from patients treated with NTLA-2001, the first-ever systemically administered in vivo CRISPR investigational therapy Presentation to include data supporting fixed dose selection in the ongoing single-dose expansion cohort of polyneuropathy
Read More

Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress

Presented updated interim data from ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy, demonstrating a single dose of NTLA-2001 resulted in rapid, deep and sustained reduction in disease-causing protein Interim readout showed treatment with NTLA-2001 at 1.0
Read More

Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

CAMBRIDGE, Mass. , May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji , R.Ph., to its board of
Read More

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference

Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading  T cells and deployable for TCR-T and CAR-T cell therapy Findings support recent development candidate initiation of NTLA-6001, an investigational allogeneic CAR-T therapy, for the treatment of
Read More
RSS FEEDS
PRINT PAGE